Screener
Ionis Pharmaceuticals IONS Deferred Tax Assets Leasing Arrangements
Deferred Tax Assets Leasing Arrangements at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:DeferredTaxAssetsLeasingArrangements.
The source filing: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:25 PM EST
- Fiscal year
- FY2026
- Accession
- 0000874015-26-000115
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Intangible and capital assets | 76,283 | 93,541 |
| Convertible debt | 1,305 | 9,310 |
| Capitalized research and development expenses | 233,485 | 323,560 |
| Long-term lease liabilities | 71,871 | 41,481 |
| Sale of future royalties | 156,870 | 148,918 |
| Other | 12,755 | 14,024 |
| Total deferred tax assets | $$1,310,891 | 1,174,111 |
| Deferred Tax Liabilities: |
Item 15. Exhibits and Financial Statement Schedules
FAQ
- What is Ionis Pharmaceuticals's deferred tax assets leasing arrangements?
- Ionis Pharmaceuticals (IONS) reported deferred tax assets leasing arrangements of $71.87M in Q4 2025.
- What does deferred tax assets leasing arrangements mean?
- Deferred tax assets generated by temporary differences in the recognition of lease-related expenses under accounting standards versus tax regulations. These represent the tax impact of lease liabilities and right-of-use assets.
Ask your AI about Ionis Pharmaceuticals's deferred tax assets leasing arrangements.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude